Matthew F Bouchonville1, Dennis T Villareal. 1. Division of Endocrinology, Diabetes, and Metabolism, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Abstract
PURPOSE OF REVIEW: The increasing prevalence of sarcopenic obesity in older adults has heightened interest in identifying the most effective treatment. This review highlights recent progress in the management, with an emphasis on lifestyle interventions and pharmacologic therapy aimed at reversing sarcopenic obesity. RECENT FINDINGS: Whereas weight loss and exercise independently reverse sarcopenic obesity, they act synergistically in combination to improve body composition and physical function, beyond which is observed with either intervention alone. Optimizing protein intake appears to have beneficial effects on net muscle protein accretion in older adults. Myostatin inhibition is associated with favorable changes in body composition in animal studies, although experience in humans is relatively limited. Testosterone and growth hormone offer improvements in body composition, but the benefits must be weighed against potential risks of therapy. GHRH-analog therapy shows promise, but further studies are needed in older adults. SUMMARY: At present, lifestyle interventions incorporating both diet-induced weight loss and regular exercise appear to be the optimal treatment for sarcopenic obesity. Maintenance of adequate protein intake is also advisable. Ongoing studies will determine whether pharmacologic therapy such as myostatin inhibitors or GHRH analogs have a role in the treatment of sarcopenic obesity.
PURPOSE OF REVIEW: The increasing prevalence of sarcopenic obesity in older adults has heightened interest in identifying the most effective treatment. This review highlights recent progress in the management, with an emphasis on lifestyle interventions and pharmacologic therapy aimed at reversing sarcopenic obesity. RECENT FINDINGS: Whereas weight loss and exercise independently reverse sarcopenic obesity, they act synergistically in combination to improve body composition and physical function, beyond which is observed with either intervention alone. Optimizing protein intake appears to have beneficial effects on net muscle protein accretion in older adults. Myostatin inhibition is associated with favorable changes in body composition in animal studies, although experience in humans is relatively limited. Testosterone and growth hormone offer improvements in body composition, but the benefits must be weighed against potential risks of therapy. GHRH-analog therapy shows promise, but further studies are needed in older adults. SUMMARY: At present, lifestyle interventions incorporating both diet-induced weight loss and regular exercise appear to be the optimal treatment for sarcopenic obesity. Maintenance of adequate protein intake is also advisable. Ongoing studies will determine whether pharmacologic therapy such as myostatin inhibitors or GHRH analogs have a role in the treatment of sarcopenic obesity.
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: Satoshi Fujita; Blake B Rasmussen; Jerson G Cadenas; Micah J Drummond; Erin L Glynn; Fred R Sattler; Elena Volpi Journal: Diabetes Date: 2007-03-09 Impact factor: 9.461
Authors: Heidi K White; Charles D Petrie; William Landschulz; David MacLean; Ann Taylor; Kenneth Lyles; Jeanne Y Wei; Andrew R Hoffman; Roberto Salvatori; Mark P Ettinger; Miriam C Morey; Marc R Blackman; George R Merriam Journal: J Clin Endocrinol Metab Date: 2009-01-27 Impact factor: 5.958
Authors: D Rudman; A G Feller; H S Nagraj; G A Gergans; P Y Lalitha; A F Goldberg; R A Schlenker; L Cohn; I W Rudman; D E Mattson Journal: N Engl J Med Date: 1990-07-05 Impact factor: 91.245
Authors: E Todd Schroeder; Ling Zheng; Kevin E Yarasheski; Dajun Qian; Yolanda Stewart; Carla Flores; Carmen Martinez; Michael Terk; Fred R Sattler Journal: J Appl Physiol (1985) Date: 2003-10-24
Authors: Caoileann H Murphy; Tyler A Churchward-Venne; Cameron J Mitchell; Nathan M Kolar; Amira Kassis; Leonidas G Karagounis; Louise M Burke; John A Hawley; Stuart M Phillips Journal: Am J Physiol Endocrinol Metab Date: 2015-03-03 Impact factor: 4.310
Authors: Caoileann H Murphy; Mahalakshmi Shankaran; Tyler A Churchward-Venne; Cameron J Mitchell; Nathan M Kolar; Louise M Burke; John A Hawley; Amira Kassis; Leonidas G Karagounis; Kelvin Li; Chelsea King; Marc Hellerstein; Stuart M Phillips Journal: J Physiol Date: 2018-04-17 Impact factor: 5.182
Authors: Dennis T Villareal; Lina Aguirre; A Burke Gurney; Debra L Waters; David R Sinacore; Elizabeth Colombo; Reina Armamento-Villareal; Clifford Qualls Journal: N Engl J Med Date: 2017-05-18 Impact factor: 91.245